Press release
Limb Girdle Muscular Dystrophy Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight
Limb Girdle Muscular Dystrophy Market
(Albany, USA) DelveInsight's "Limb Girdle Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Limb Girdle Muscular Dystrophy, historical and forecasted epidemiology as well as the Limb Girdle Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Limb Girdle Muscular Dystrophy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Limb Girdle Muscular Dystrophy market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Limb Girdle Muscular Dystrophy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Limb Girdle Muscular Dystrophy market.
Request for a Free Sample Report @ Limb Girdle Muscular Dystrophy Market Forecast [https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some facts of the Limb Girdle Muscular Dystrophy Market Report are:
* According to DelveInsight, Limb Girdle Muscular Dystrophy market size is expected to grow at a decent CAGR by 2032.
* Leading Limb Girdle Muscular Dystrophy companies working in the market are ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.
* Key Limb Girdle Muscular Dystrophy Therapies expected to launch in the market are SRP-6004, LION-101, BBP-418 (ribitol), and others.
* On February 2024, Sarepta Therapeutics announced results of a multicenter, global study of the effects of a single systemic dose of SRP-9003 on beta-sarcoglycan (-SG) gene expression in participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). This study will consist of both ambulatory participants (Cohort 1) and non-ambulatory participants (Cohort 2).
* On October 2023, aTyr Pharma, Inc. announced results of an Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies.
* On April 2023, ML Bio Solutions announced results of an open label study in ambulatory and non-ambulatory subjects with LGMD2I (also known as LGMD R9) previously enrolled in the natural history Study MLB-01-001. This is a study to determine the safety and tolerability of ascending dose levels of BBP-418 in those subjects.
Limb Girdle Muscular Dystrophy Overview
Limb-girdle muscular dystrophy (LGMD) encompasses a group of genetic disorders characterized by progressive weakness and wasting of the muscles, primarily affecting the muscles around the shoulders and hips. It can manifest at any age, with onset typically occurring in childhood, adolescence, or adulthood. LGMD is caused by mutations in various genes responsible for muscle function and structure.
Limb-girdle muscular dystrophy (LGMD) Symptoms vary widely among individuals but often include difficulty rising from a seated position, climbing stairs, and lifting objects. As the disease progresses, individuals may experience muscle weakness and atrophy in other areas of the body, leading to mobility limitations and potential respiratory complications in severe cases.
Limb-girdle muscular dystrophy (LGMD) Diagnosis involves a combination of clinical evaluation, genetic testing, electromyography (EMG), and muscle biopsy. While there is currently no cure for LGMD, management focuses on symptom relief, maintaining mobility, and optimizing quality of life. This may involve physical therapy, assistive devices, respiratory support, and ongoing monitoring for potential complications.
Research into potential treatments, including gene therapy and pharmacological interventions, is ongoing and offers hope for improved outcomes in the future. Additionally, supportive resources and patient advocacy organizations play a crucial role in providing information, support, and community for individuals and families affected by Limb-girdle muscular dystrophy (LGMD).
Learn more about Limb Girdle Muscular Dystrophy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Limb Girdle Muscular Dystrophy Market
The Limb Girdle Muscular Dystrophy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Limb Girdle Muscular Dystrophy market trends by analyzing the impact of current Limb Girdle Muscular Dystrophy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Limb Girdle Muscular Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Limb Girdle Muscular Dystrophy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight's' estimates, the limb girdle muscular dystrophy market in 7MM is expected to show a positive growth, during the forecast period (2023-2032), mainly attributed to anticipated launch of emerging therapy and the increasing cases of LGMD.
Limb Girdle Muscular Dystrophy Epidemiology
The Limb Girdle Muscular Dystrophy epidemiology section provides insights into the historical and current Limb Girdle Muscular Dystrophy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Limb Girdle Muscular Dystrophy market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Limb Girdle Muscular Dystrophy Epidemiology @ Limb Girdle Muscular Dystrophy Market Dynamics [https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Limb Girdle Muscular Dystrophy Drugs Uptake
This section focuses on the uptake rate of the potential Limb Girdle Muscular Dystrophy drugs recently launched in the Limb Girdle Muscular Dystrophy market or expected to be launched in 2019-2032. The analysis covers the Limb Girdle Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Limb Girdle Muscular Dystrophy Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Limb Girdle Muscular Dystrophy market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Currently, there is no known cure for LGMD. However, there are supportive therapies designed to manage and alleviate its symptoms. The approach to LGMD management is individualized, focusing on addressing specific symptoms that each patient experiences. Treatment options may involve physical and occupational therapy to enhance muscle strength and prevent contractures, the utilization of assistive devices like canes, braces, walkers, or wheelchairs to aid mobility, corrective surgery for skeletal issues like scoliosis, and regular monitoring of cardiac and respiratory health for potential complications associated with certain LGMD subtypes.
Limb Girdle Muscular Dystrophy Pipeline Development Activities
The Limb Girdle Muscular Dystrophy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Limb Girdle Muscular Dystrophy key players involved in developing targeted therapeutics.
Limb-girdle Muscular Dystrophy Pipeline Therapies and Companies
* SRP-6004: Sarepta Therapeutics, Inc.
* LION-101: Asklepios Biopharmaceutical, Inc.
* BBP-418 (ribitol): ML Bio Solutions, Inc.
Request for a sample report to understand more about the Limb Girdle Muscular Dystrophy pipeline development activities @ https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Limb Girdle Muscular Dystrophy Therapeutics Assessment
Major key companies are working proactively in the Limb Girdle Muscular Dystrophy Therapeutics market to develop novel therapies which will drive the Limb Girdle Muscular Dystrophy treatment markets in the upcoming years are ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.
Learn more about the emerging Limb Girdle Muscular Dystrophy therapies & key companies @ https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market [https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Limb Girdle Muscular Dystrophy Report Key Insights
1. Limb Girdle Muscular Dystrophy Patient Population
2. Limb Girdle Muscular Dystrophy Market Size and Trends
3. Key Cross Competition in the Limb Girdle Muscular Dystrophy Market
4. Limb Girdle Muscular Dystrophy Market Dynamics (Key Drivers and Barriers)
5. Limb Girdle Muscular Dystrophy Market Opportunities
6. Limb Girdle Muscular Dystrophy Therapeutic Approaches
7. Limb Girdle Muscular Dystrophy Pipeline Analysis
8. Limb Girdle Muscular Dystrophy Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Limb Girdle Muscular Dystrophy Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Limb Girdle Muscular Dystrophy Competitive Intelligence Analysis
4. Limb Girdle Muscular Dystrophy Market Overview at a Glance
5. Limb Girdle Muscular Dystrophy Disease Background and Overview
6. Limb Girdle Muscular Dystrophy Patient Journey
7. Limb Girdle Muscular Dystrophy Epidemiology and Patient Population
8. Limb Girdle Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Limb Girdle Muscular Dystrophy Unmet Needs
10. Key Endpoints of Limb Girdle Muscular Dystrophy Treatment
11. Limb Girdle Muscular Dystrophy Marketed Products
12. Limb Girdle Muscular Dystrophy Emerging Therapies
13. Limb Girdle Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Limb Girdle Muscular Dystrophy Market Outlook (7 major markets)
16. Limb Girdle Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Limb Girdle Muscular Dystrophy Market
18. Limb Girdle Muscular Dystrophy Market Drivers
19. Limb Girdle Muscular Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=limb-girdle-muscular-dystrophy-market-forecast-2032-epidemiology-fda-approvals-therapies-clinical-trials-and-companies-by-delveinsight]
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Limb Girdle Muscular Dystrophy Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight here
News-ID: 3460091 • Views: …
More Releases from ABNewswire
Custom Packaging Boxes With Logo: Branding Guide
Image: https://www.abnewswire.com/upload/2026/02/a85b0085c76a144c61cb76a8aed92b66.jpg
In today's market, your product should stand out. Great products are crucial. But presentation could make or damage first impressions. This is where custom packaging containers play an important position. Packaging that carries your brand is no longer an afterthought. It is a strategic tool for brand success.
Customers decide great inside seconds. Packaging is frequently the primary tangible interplay they've with your emblem. It shapes their expectations and feelings.…
Nutritionsly Recognizes CoreAge Rx as the World's Best GLP-1 Provider, Highlight …
Image: https://www.abnewswire.com/upload/2026/02/49a060b2c5ce8e5e3c8c09910a5507f2.jpg
Nutritionsly has named CoreAge Rx as the Best GLP-1 provider in the world [https://www.nutritionsly.com/complete-review-of-coreage-rx-and-what-makes-it-the-best-glp-1-brand-in-2026/], recognizing the company's transparent pricing structure, licensed healthcare oversight, and comprehensive telemedicine-based weight management program. The recognition highlights CoreAge Rx's continued expansion as a structured and accessible provider of GLP-1 medications delivered through a streamlined virtual care model.
CoreAge Rx [https://www.coreagerx.com/] provides access to GLP-1 medications including semaglutide and tirzepatide through a fully integrated telemedicine platform.…
The LegalTech Platform Lawyers Actually Open Every Morning - How Phenomenon Stud …
(By Iryna Huk - Project Manager Lead, Phenomenon Studio February 18, 2026 LegalTech Compliance SaaS Web App Design)
Key Takeaways
LegalTech platforms fail adoption not because lawyers distrust technology - but because the products look and behave like they were designed for someone else. ClauseGuard was built with a user research foundation that put practicing attorneys in every design decision from day one.
Choosing web and design services [https://phenomenonstudio.com/web-design-services] that understand institutional trust…
Link Collection: The Smart Way to Organize, Share, and Discover the Best Online …
In today's fast-paced digital world, finding, saving, and managing useful links can quickly become overwhelming. Whether you are a student, entrepreneur, content creator, or casual internet user, keeping track of valuable websites is essential. This is where https://linkparty.clickn.co.kr/ comes in.
A link collection is a curated collection of useful, trending, and reliable links gathered in one convenient place. Platforms like http://linkparty.clickn.co.kr make it easier than ever to organize online resources, discover…
More Releases for Limb
Critical Limb Ischemia Pipeline: Advancing Regenerative Therapies and Novel Inte …
The treatment landscape for Critical Limb Ischemia (CLI), the most severe form of peripheral arterial disease, is evolving rapidly as the limitations of conventional revascularization and amputation drive demand for novel therapeutic approaches. Breakthroughs in angiogenesis, stem cell therapies, gene therapy, and immunomodulation are reshaping the future of CLI management, offering hope for tissue regeneration and improved limb salvage outcomes.
DelveInsight's "Critical Limb Ischemia - Pipeline Insight, 2025" provides an in-depth…
Limb Prosthetics Market Size And Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- Limb Prosthetics Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027.
Limb Prosthetics Market Growth Driver
The limb prosthetics market is experiencing significant growth, driven by several key factors, including the rising prevalence of limb loss due to diabetes, vascular diseases, and traumatic injuries. As…
Pediatric Lower Limb Prosthetics Market
The "Pediatric Lower Limb Prosthetics Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Pediatric Lower Limb Prosthetics Market, 2024-2031
Verified Market Research's most recent report, "Pediatric Lower Limb Prosthetics Market: Global Industry Trends, Share, Size, Growth, Opportunity and…
Limb Prosthetics Market 2024 Strategic Assessment
In recent years, the global Limb Prosthetics Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Limb Prosthetics Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Lower Limb Rehabilitation Exoskeleton Robot | WALKBOT
The exoskeleton robotic rehabilitation devices made by WALKBOT provide robot-assisted gait training rehabilitation systems for musculoskeletal disabilities.
Walkbot Advanced solutions
The Walkbot, lower limb rehabilitation robot provides exciting customized 3-dimensional augmented reality exercise games so that their clients actually do not perceive the gait training as a form of therapy. Rather, they enjoy walking in interactive and ecologically natural or virtual environments as used by the software.
Game-Like Rehabilitation Training: Go World immerses…
Critical Limb Ischemia - Drug Pipeline Landscape, 2022
Critical limb ischemia is a serious form of peripheral arterial disease, or PAD where severe blockage in the arteries of the lower extremities (hands, feet and legs) occurs, which markedly reduces blood-flow. It results in severe pain and even skin ulcers or sores.
Peripheral artery disease causes chronic limb-threatening ischemia. Other causes of limb ischemia include embolisms, trauma and compartment syndrome.
The most common symptom of critical limb ischemia is ischemic…
